213 related articles for article (PubMed ID: 35452102)
1. Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals.
De Marco L; D'Orso S; Pirronello M; Verdiani A; Termine A; Fabrizio C; Capone A; Sabatini A; Guerrera G; Placido R; Sambucci M; Angelini DF; Giannessi F; Picozza M; Caltagirone C; Salvia A; Volpe E; Balice MP; Rossini A; Rötzschke O; Giardina E; Battistini L; Borsellino G
JAMA Netw Open; 2022 Apr; 5(4):e2210871. PubMed ID: 35452102
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals.
Emmelot ME; Vos M; Boer MC; Rots NY; van Els CACM; Kaaijk P
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680141
[TBL] [Abstract][Full Text] [Related]
3. Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals.
Emmelot ME; Vos M; Boer MC; Rots NY; de Wit J; van Els CACM; Kaaijk P
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891550
[TBL] [Abstract][Full Text] [Related]
4. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8
Redd AD; Nardin A; Kared H; Bloch EM; Abel B; Pekosz A; Laeyendecker O; Fehlings M; Quinn TC; Tobian AAR
mBio; 2022 Apr; 13(2):e0361721. PubMed ID: 35229637
[TBL] [Abstract][Full Text] [Related]
5. T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern.
Cohen H; Rotem S; Elia U; Bilinsky G; Levy I; Chitlaru T; Bar-Haim E
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215940
[TBL] [Abstract][Full Text] [Related]
6. T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.
Li Y; Wang X; Jin J; Ma Z; Liu Y; Zhang X; Su B
J Med Virol; 2022 Aug; 94(8):3998-4004. PubMed ID: 35474581
[TBL] [Abstract][Full Text] [Related]
7. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab.
Madelon N; Heikkilä N; Sabater Royo I; Fontannaz P; Breville G; Lauper K; Goldstein R; Grifoni A; Sette A; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS
JAMA Neurol; 2022 Apr; 79(4):399-404. PubMed ID: 35212717
[TBL] [Abstract][Full Text] [Related]
8. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
Gao Y; Cai C; Grifoni A; Müller TR; Niessl J; Olofsson A; Humbert M; Hansson L; Österborg A; Bergman P; Chen P; Olsson A; Sandberg JK; Weiskopf D; Price DA; Ljunggren HG; Karlsson AC; Sette A; Aleman S; Buggert M
Nat Med; 2022 Mar; 28(3):472-476. PubMed ID: 35042228
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron.
Mazzoni A; Vanni A; Spinicci M; Capone M; Lamacchia G; Salvati L; Coppi M; Antonelli A; Carnasciali A; Farahvachi P; Giovacchini N; Aiezza N; Malentacchi F; Zammarchi L; Liotta F; Rossolini GM; Bartoloni A; Cosmi L; Maggi L; Annunziato F
Front Immunol; 2022; 13():801431. PubMed ID: 35154116
[TBL] [Abstract][Full Text] [Related]
10. T cell responses to SARS-CoV-2 spike cross-recognize Omicron.
Keeton R; Tincho MB; Ngomti A; Baguma R; Benede N; Suzuki A; Khan K; Cele S; Bernstein M; Karim F; Madzorera SV; Moyo-Gwete T; Mennen M; Skelem S; Adriaanse M; Mutithu D; Aremu O; Stek C; du Bruyn E; Van Der Mescht MA; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Mendes A; Strydom A; Venter M; Giandhari J; Naidoo Y; Pillay S; Tegally H; Grifoni A; Weiskopf D; Sette A; Wilkinson RJ; de Oliveira T; Bekker LG; Gray G; Ueckermann V; Rossouw T; Boswell MT; Bhiman JN; Moore PL; Sigal A; Ntusi NAB; Burgers WA; Riou C
Nature; 2022 Mar; 603(7901):488-492. PubMed ID: 35102311
[TBL] [Abstract][Full Text] [Related]
11. BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality.
Jung MK; Jeong SD; Noh JY; Kim DU; Jung S; Song JY; Jeong HW; Park SH; Shin EC
Nat Microbiol; 2022 Jun; 7(6):909-917. PubMed ID: 35577972
[TBL] [Abstract][Full Text] [Related]
12. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
13. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
14. Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant.
Nesamari R; Omondi MA; Baguma R; Höft MA; Ngomti A; Nkayi AA; Besethi AS; Magugu SFJ; Mosala P; Walters A; Clark GM; Mennen M; Skelem S; Adriaanse M; Grifoni A; Sette A; Keeton RS; Ntusi NAB; Riou C; Burgers WA
Cell Host Microbe; 2024 Feb; 32(2):162-169.e3. PubMed ID: 38211583
[TBL] [Abstract][Full Text] [Related]
15. Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
Fries L; Formica N; Mallory RM; Zhou H; Plested JS; Kalkeri R; Moldovan I; Patel N; Albert G; Robinson M; Cho I; Chau G; Dubovsky F; Glenn GM;
J Infect Dis; 2023 Sep; 228(6):734-741. PubMed ID: 37210741
[TBL] [Abstract][Full Text] [Related]
16. Reduced binding activity of vaccine serum to omicron receptor-binding domain.
Li M; Weng S; Wang Q; Yang Z; Wang X; Yin Y; Zhou Q; Zhang L; Tao F; Li Y; Jia M; Yang L; Xin X; Li H; Kang L; Wang Y; Wang T; Li S; Kong L
Front Immunol; 2022; 13():960195. PubMed ID: 35967350
[TBL] [Abstract][Full Text] [Related]
17. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
18. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
[TBL] [Abstract][Full Text] [Related]
20. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals.
Naranbhai V; Nathan A; Kaseke C; Berrios C; Khatri A; Choi S; Getz MA; Tano-Menka R; Ofoman O; Gayton A; Senjobe F; Zhao Z; St Denis KJ; Lam EC; Carrington M; Garcia-Beltran WF; Balazs AB; Walker BD; Iafrate AJ; Gaiha GD
Cell; 2022 Mar; 185(6):1041-1051.e6. PubMed ID: 35202566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
